AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright

Go back to AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright

Anaptys Announces Participation in November and December Investor Conferences

November 5, 2024 4:15 PM EST

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA

Format Fireside chat and one-on-one investor meetingsDate and Time Wednesday, Nov. 13, 2024 at 1:30pm ET / 10:30am PT

Stifel 2024 Healthcare... More

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

November 5, 2024 4:15 PM EST

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February 2025Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonistReiterating cash runway through year-end 2026

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative... More